CVS Steps into Biologic Drug Territory with Store-Brand Monoclonal Antibody Launch
Monday, 29 April 2024, 09:30
CVS's Move into Biosimilars
CVS is set on developing a store brand monoclonal antibody, a biosimilar medication intended to replicate the effects of established blockbuster drugs. This innovative approach positions CVS to directly benefit from the increasing trend of biosimilar utilization.
Monoclonal Antibodies: A Game-Changer
Monoclonal antibodies are revolutionizing treatment options by offering more affordable alternatives to costly biologic drugs. CVS's foray into manufacturing these biosimilars underscores the company's commitment to providing accessible healthcare solutions.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.